CYTO - Auris Medical Holding

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• AIM, PTE and PHIO among mid-day movers
• Lixte, BioCardia top healthcare gainers; Hoth, Altamira lead losers' pack
• Altamira Therapeutics GAAP EPS of -CHF1.31, revenue of CHF0.06M
• Altamira spikes on publication of lab data for COVID-19 nasal spray
• Altamira rises on regulatory nod to begin study for potential COVID-19 therapy
• Altamira and Nuance in pact to sell nasal spray Bentrio in China and South Korea
• Altamira in pact with Avernus Pharma to market Bentrio in gulf region
• Altamira Therapeutics sets up over-the-counter consumer health business unit
• Altamira Therapeutics nasal spray Bentrio approved in Malaysia
• Altamira Therapeutics appoints chief development officer; gets NIH grant
• Altamira Therapeutics rises 26% over positive update on antiviral nasal spray Bentrio
• Altamira Therapeutics files for $79M mixed securities offering
• Altamira Therapeutics soars 9% as Bentrio nasal spray gets US FDA review
• Altamira Therapeutics reports 1H results
• Auris Medical launches new corporate website
• Auris Medical shares surge on data from Bentrio SARS-CoV-2 preclinical studies
• Auris Medical shares rise after picking colorectal cancer as the first indication for OligoPhore
• Auris Medical shares rise on OligoPhore Lymphoma study results
• Auris Medical soars 10% on acquisition of Trasir Therapeutics and plans for strategic repositioning
• Auris Medical starts preparations for COVID-19 trial with Bentrio in India